Capitaline

Analyst Meet / AGM 18-Feb-21

Conference Call

Advanced Enzymes Technologies

Expect to double its revenues in 5 years

Advanced Enzymes Technologies held a conference call on 15^th February 2021 to discuss the results for the quarter ended Dec'20 and way forward. Mr. Mukund Kabra- Director and Mr. Beni Prasad Rauka- Group CFO of the company addressed the call.
Highlights of the Concall

Q3FY21 sales were up 23% YoY at Rs 137.7 crore led by 35% YoY growth in Human Healthcare sales to Rs 108.9 crore, 12% increase in Industrial division sales to Rs 18.3 crore while Animal Healthcare revenues were down 30% to Rs 10.5 crore

9MFY21 sales were up 10% YoY at Rs 368.6 crore led by 17% YoY growth in Human Healthcare sales to Rs 286.1 crore while Industrial division revenue fell 1% to Rs 48.1 crore while Animal Healthcare revenues were down 16% to Rs 34.4 crore

Revenue of US subsidiary has gone up by 7.5% during this quarter, and by 1%, during nine months, even after it made a loss of sale of 5.47 million from the bigger customer in the first nine months of the last financial year.

Supply chain and logistical issues faced during the lock downs are being solved slowly, however freight costs have gone up significantly, in some cases, three times to four times.

All manufacturing units are running efficiently and progressing well towards normalcy

Top 10 customer's forms 47% of total revenues during the quarter while for 9MFY21 it was 41%.

R&D expenditure as percentage of total sales is 4.5%

Currently cash and cash equivalent is about Rs 279 crore and receivables is 70 days.

The company mentioned that annual performance for the company is more important than quarterly performance

The company has enough capacity but once capacity utilisation reaches 80%, new capex will be planned. Currently every year Rs 10-12 of maintenance capex is required

Europe sales are being impacted amid second Covid wave

The company plans to double its revenues in next five years. Major growth drivers in Human health care will be biocatalyst, probiotics and nutraceuticals sales where B2C sales are expected to grow in the coming years. Animal feed is also expected to grow as pandemic is almost over. In industrial process bakery would be a growth driver in growth areas.

Previous News

Advanced Enzyme Technologies fixes record date for final dividend
( Market Beat - Reports 10-Aug-21 17:26 )

Advanced Enzyme soars on positive breakthrough in RCTs of COVID-fatigue treating enzymes
( Hot Pursuit - 13-Sep-21 11:15 )

Advanced Enzyme Techs. announces board meeting date
( Corporate News - 08-Aug-23 19:29 )

Advanced Enzyme Tech gains after strong Q4 performance
( Hot Pursuit - 15-May-23 10:08 )

Advanced Enzyme Technologies
( Results - Analysis 10-Feb-20 11:49 )

Advanced Enzyme Technologies consolidated net profit rises 37.46% in the December 2019 quarter
( Results - Announcements 06-Feb-20 16:36 )

Advanced Enzyme Techs. to declare Quarterly Result
( Corporate News - 02-Nov-23 15:11 )

Advanced Enzyme Technologies receives organic certification from APEDA
( Corporate News - 12-Jul-18 11:36 )

Advanced Enzyme Techs. to declare Quarterly Result
( Corporate News - 17-May-19 11:45 )

Advanced Enzyme Technologies standalone net profit rises 85.61% in the March 2017 quarter
( Results - Announcements 29-May-17 12:53 )

Advanced Enzyme Technologies consolidated net profit declines 41.43% in the June 2017 quarter
( Results - Announcements 11-Sep-17 16:41 )